Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.
Key Points
Twenty-four of 32 analysts covering Intuitive Surgical rate the stock as a "buy" or "strong buy."
However, Intuitive faces multiple headwinds that are pressuring its growth.
While these headwinds are real, the company's tailwinds should be stronger over the long run.
- 10 stocks we like better than Intuitive Surgical ›
Count Intuitive Surgical (NASDAQ: ISRG) among the biggest healthcare losers of 2026. The medical device stock is down close to 30% year to date. Its performance was even worse. By late July, Intuitive Surgical's share price had plunged more than 40% since the beginning of the year.
Despite this dismal trajectory, Wall Street remains overwhelmingly bullish about Intuitive Surgical. Of the 32 analysts surveyed by S&P Global (NYSE: SPGI) in September, 24 rated the stock as a "buy" or "strong buy." Only one of the other eight analysts recommended selling Intuitive.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
But is Wall Street dead wrong about this beaten-down stock?
Image source: Intuitive Surgical.
Several headwinds
To be sure, a stock doesn't sink as much as Intuitive Surgical has so far this year without facing some serious headwinds. Intuitive's growth is slowing, which is especially problematic for a stock trading at a forward price-to-earnings multiple over 33.
The company isn't gaining as much traction in the Chinese market as it would like. Intuitive Surgical CEO David Rosa admitted in the 2026 second-quarter earnings call that "the environment remains challenging" in China due to increased competition and government pricing policies.
Speaking of increased competition, Intuitive Surgical faces more of it elsewhere, too. After having the robotic surgical systems market to itself for years, Intuitive now must battle healthcare giants Johnson & Johnson (NYSE: JNJ), Medtronic (NYSE: MDT), and Stryker (NYSE: SYK), as well as smaller rivals.
Government actions aren't just a problem for Intuitive in China, either. The expiration of subsidies for Affordable Care Act (ACA) health plans in the U.S. is also impacting procedure growth for the company's da Vinci surgical robots.
Then there's the impact of GLP-1 drugs. Intuitive Surgical CFO Jamie Samath noted in the Q2 call that U.S. da Vinci bariatric procedure volumes fell by high single digits during the quarter due to increasing GLP-1 usage.
My honest answer
With all of these headwinds, is Wall Street wrong to be bullish about Intuitive Surgical? My honest answer is... not at all.
Yes, the headwinds are real. However, they're not showstoppers. For example, even with Intuitive's challenges in China, the company's revenue in Asia still jumped 20% year over year in Q2. Increased competition doesn't appear to be hurting Intuitive much outside of China.
Samath said that the ACA subsidies are only having a "modest adverse impact." And the effects of GLP-1 drugs on Intuitive's business seem to be primarily limited to bariatric procedures.
Importantly, Intuitive Surgical has tailwinds that are even bigger than its tailwinds over the long run. Aging demographic trends worldwide should drive demand for robotic surgical systems. Technological advances should expand the number of procedures that can be performed with robotic assistance.
I don't always agree with analysts. But I think Wall Street is 100% right to be upbeat about this healthcare stock.
Should you buy stock in Intuitive Surgical right now?
Before you buy stock in Intuitive Surgical, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Intuitive Surgical wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $379,123!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,396,103!*
Now, it’s worth noting Stock Advisor’s total average return is 933% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of October 1, 2026.
Keith Speights has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical, Medtronic, and S&P Global. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.
Recommended Articles
